BioNTech SE (XBUL:22UA) Notes Receivable: лв0 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XBUL:22UA BioNTech SE XBUL:22UA
61 GF Score
Price лв88.20
GF Value лв71.55
! 5 Warning Signs
View Full Analysis

What is BioNTech SE Notes Receivable?

BioNTech SE XBUL:22UA 61 Notes Receivable is лв0 Mil as of Jun. 2026. GuruFocus rates XBUL:22UA with a GF Score™ of 61/100 and a GF Value™ of лв71.55. The stock has 5 warning signs investors should review.

BioNTech SE's Notes Receivable for the quarter that ended in Jun. 2026 was лв0 Mil.

BioNTech SE Notes Receivable Historical Data

* Premium members only.

The historical data trend for BioNTech SE's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

BioNTech SE Notes Receivable Chart

BioNTech SE Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BioNTech SE Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
XBUL:22UA
61GF Score
BioNTech SE XBUL:22UA
Notes Receivable is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

BioNTech SE Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.

Frequently Asked Questions Learn more about Notes Receivable →
What does a Notes Receivable of лв0 Mil mean?
BioNTech SE (XBUL:22UA) has a Notes Receivable of лв0 Mil as of Jun. 2026. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BioNTech SE and its competitors.
Is BioNTech SE's Notes Receivable too high?
BioNTech SE's current Notes Receivable is лв0 Mil. Overall, BioNTech SE has a GF Score™ of 61/100, reflecting its overall financial health beyond just this single metric.
How does BioNTech SE's Notes Receivable compare to INSM and INCY?
BioNTech SE's Notes Receivable of лв0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Notes Receivable for a Biotechnology company?
A good Notes Receivable depends on the Biotechnology industry context. However, Notes Receivable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Notes Receivable mean?
A high Notes Receivable can signal that a stock is expensive relative to its fundamentals. Notes Receivable is an unconditional promise to receive a definite sum of money within one year. View historical data on BioNTech SE and its competitors. BioNTech SE's current Notes Receivable is лв0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioNTech SE stock overvalued right now?
BioNTech SE (XBUL:22UA) has a current Notes Receivable of лв0 Mil. The stock's GF Value™ is лв71.55, compared to a current price of лв88.20 — trading 23.3% above its estimated fair value. The current Notes Receivable is лв0 Mil. BioNTech SE's overall GF Score™ is 61/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Notes Receivable calculated?
Notes Receivable is calculated from a company's financial statements. For BioNTech SE (XBUL:22UA), the current Notes Receivable is лв0 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is BioNTech SE (XBUL:22UA) Overvalued in 2026?

Based on GuruFocus' analysis, BioNTech SE stock appears to be overvalued. The current stock price of лв88.20 is trading 23.3% above its estimated GF Value™ of лв71.55.

Key valuation signals for XBUL:22UA:

  • Notes Receivable: лв0 Mil
  • GF Value™: лв71.55 vs. price of лв88.20 (23.3% above fair value)
  • GF Score™: 61/100 with 5 warning signs

No single metric tells the full story. See the XBUL:22UA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

BioNTech SE Business Description

Address An der Goldgrube 12, Mainz, RP, DEU, D-55131
BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens and neoantigens; monospecific and bispecific antibodies; and antibody-drug conjugates, or ADCs. Comirnaty, its Pfizer-partnered covid vaccine, is its first commercialized product.
61GF Score

Get the complete analysis for XBUL:22UA

Notes Receivable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

лв88.20
Price
лв71.55
GF Value